Supplementary Table 2.
GIST series reported in the literature
| References | Rectal GIST/total, n | Surgery | Chemotherapy | Radiotherapy | Outcome |
|---|---|---|---|---|---|
| Terada 2009[70] | 1/31 | NA | Imatinib mesylate in 6 cases | NA | OS: 4 of 31 patients developed metastasis and died of disease; 27 alive without disease |
| Wang et al. 2015[27] | 8/20 | 19/20 underwent R0 resection. 7 rectal GISTs, of which 3 had transanal local excision, 2 were excised with HAR, 1 was excised with Hartmann's procedure and 1 with Miles’ procedure | 1 rectal GIST patient received imatinib mesylate | NA | Follow-up: 49.5 months (range, 10.5–94.4 months) 5 patients had recurrence, of whom 4 had rectal tumors and 1 had an enterocoelial tumor |
| Cuaron et al. 2013[15] | 1/15 | NA | Sunitinib | 300 cGy × 10 fractions (n = 8). Other schemes 180 cGy × 25, 200 cGy × 25. SBRT for 9 tumors (2400 cGy × 1, n = 2; 900 cGy × 3, n = 2; 800 cGy × 3, n = 1; 600 cGy × 5, n = 2; and 500 cGy × 5, n = 2). Three patients with a partial course of 300 cGy × 10 | The median follow-up 5.1 months 12 of the 15 (80%) died. Among the 18 tumors that were symptomatic at presentation at least partial palliation was achieved in 17 (94.4%). completely palliated in eight tumors (44.4%) Partial radiographic response was seen in 35.3% (n = 6). Stable disease 52.9% (n = 9), progressive disease 11.8% (n = 2). Among tumors treated with SBRT partial response was seen in 62.5% (n = 5), stable disease was seen in 25.0% (n = 2), and progressive disease in 12.5% (n = 1). The estimated 6 months local progression-free survival was 57.0%, MS 6.6 months, estimated 6 months OS 57.8% |
| Kapoor et al. 2013[71] | 1/49 | NA | Imatinib/sunitinib | NA | 3-year RFS 38% |
| Jakob et al. 2013[25] | 39 | 36/38 | Imatinib | None | Of 4 patients with metachronous peritoneal metastasis, 3 had undergone transabdominal surgery. Another patient with secondary peritoneal metastases had been treated with local excision (R1 at pathology). Three patients with secondary metastases died of disease at 18, 46, and 102 months after resection of the primary tumor. Of 36 patients who underwent resection for primary tumor, five developed local recurrences. Median time to recurrence was 12 months (range 2–70 months) from the date of surgery |
| Fujimoto et al. 2014[72] | 5 | Laparoscopic sphincter-preserving surgery after 4–12 months | Neoadjuvant imatinib treatment | None | No recurrence occurred in all patients over 1–4 years |
| Farid et al. 2013[73] | 9/109 | Curative surgery with R0 resection | Adjuvant imatinib | None | Relapse 67% MS 141 months |
| Pai et al. 2016[74] | 13 | Three patients underwent intersphincteric resection (33.3%). For remaining patients, APR was performed | Neoadjuvant imatinib and adjuvant imatinib | None | One patient developed distant metastasis and none of the patients developed local recurrence |
| Zanwar et al. 2016[23] | 26 | Sphincter-sparing surgery/intersphincteric resection. In patients not amenable for sphincter preservation, an abdominoperineal resection or a pelvic exenteration based on local extent of the tumor | Imatinib for large tumors (>5 cm) Adjuvant imatinib in patients with high-risk recurrence criteria | None | Median PFS 120 months in the whole cohort whereas median OS was not reached 4-year PFS was 81% and OS was 100% Median DFS in upfront surgery 70 months, neoadjuvant imatinib group 120 months (P = 0.039). One patient had died |
GISTs: Gastrointestinal stromal tumors; DFS: Disease-free survival; APR: Abdominoperineal resection; MS: Median survival; OS: Overall survival; PFS: Progression free survival; NA: Not available; RFS: Relapse free survival; HAR: High anterior resection; SBRT: Stereotactic body radiation therapy; hypofractionation of ≥500 cGy per fraction utilizing image guidance for delivery.